Neurocrine Biosciences Reports Fourth Quarter and Full-Year 2020 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/8/2026
- Wall St falls as Trump's Iran remarks rattle investors; Broadcom gains
- Oil prices jump 7% as US-Iran truce buckles under fresh hostilities
- Nvidia is up just 3% YTD while SOX surges 82% — what’s holding it back?
- BofA says S&P 500 technicals point to corrective Q3
- Alibaba rallies 12% after report of narrowing losses sparks pre-earnings optimism
- Morgan Stanley Reiterates Overweight Rating on Rocket Lab USA (RKLB), Bull Case Raised to $293
- Fiserv president resigns, interim leaders named for financial unit
- Nasdaq sinks as AI worries hit chipmakers
- Crude Inventory Rose 3 Million Barrels Last Week - EIA
- GameStop stockholders approve share count increase to 2.5 billion
Neurocrine Biosciences (NBIX) Tops Q4 EPS by 37c
February 4, 2021 4:35 PM ESTNeurocrine Biosciences (NASDAQ: NBIX) reported Q4 EPS of $0.91, $0.37 better than the analyst estimate of $0.54. Revenue for the quarter came in at $247.9 million versus the consensus estimate of $260.49 million.
"In 2020, we served more patients with tardive dyskinesia than ever before despite the pandemic... More
